$AQST
Aquestive Therapeutics, Inc. Stock $aqst

$aqst Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000162828022027580 Filed on November 01, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$10.68M	$11.46M
YoY Change	-3.57%	-13.73%
Cost Of Revenue	$5.305M	$4.625M
YoY Change	57.61%	5.11%
Gross Profit	$5.377M	$6.838M
YoY Change	-30.28%	-23.06%
Gross Profit Margin	50.34%	59.65%
Selling, General & Admin	$11.81M	$12.46M
YoY Change	-21.15%	2.72%
% of Gross Profit	219.68%	182.2%
Research & Development	$4.278M	$3.232M
YoY Change	-2.77%	-31.61%
% of Gross Profit	79.56%	47.27%
Depreciation & Amortization	$397.0K	$557.0K
YoY Change	-45.69%	-23.07%
% of Gross Profit	7.38%	8.15%
Operating Expenses	$16.09M	$15.69M
YoY Change	-16.98%	-6.91%
Operating Profit	-$10.71M	-$8.853M
YoY Change	-8.19%	11.11%
Interest Expense	-$1.639M	$1.649M
YoY Change	-52.55%	-40.83%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$12.35M	-$12.54M
YoY Change	-57.33%	-13.87%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.35M	-$12.54M
YoY Change	-57.33%	-13.87%
Net Earnings / Revenue	-115.63%	-109.36%
Basic Earnings Per Share		-$0.23
Diluted Earnings Per Share	-$0.23	-$0.23
COMMON SHARES
Basic Shares Outstanding	54.16M shares	53.35M shares
Diluted Shares Outstanding		53.42M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.27M	$18.65M
YoY Change	-2.68%	-40.16%
Cash & Equivalents	$27.27M	$18.65M
Short-Term Investments
Other Short-Term Assets	$2.131M	$1.976M
YoY Change	-30.74%	-22.2%
Inventory	$5.780M	$6.725M
Prepaid Expenses
Receivables	$4.704M	$10.74M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$39.89M	$38.09M
YoY Change	-15.6%	-24.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.901M	$4.284M
YoY Change	56.3%	-17.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.451M	$5.893M
YoY Change	-6.55%	-14.66%
Total Long-Term Assets	$15.79M	$13.76M
YoY Change	7.15%	-8.78%
TOTAL ASSETS
Total Short-Term Assets	$39.89M	$38.09M
Total Long-Term Assets	$15.79M	$13.76M
Total Assets	$55.68M	$51.85M
YoY Change	-10.19%	-20.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.946M	$11.07M
YoY Change	19.63%	78.15%
Accrued Expenses	$8.373M	$7.733M
YoY Change	-4.16%	1.43%
Deferred Revenue	$1.513M	$774.0K
YoY Change	97.78%	0.91%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$18.70M	$14.23M
YoY Change	823.46%	84.14%
Total Short-Term Liabilities	$39.68M	$36.56M
YoY Change	80.65%	46.01%
LONG-TERM LIABILITIES
Long-Term Debt	$33.45M	$38.68M
YoY Change	-35.12%	18.37%
Other Long-Term Liabilities	$101.1M	$2.159M
YoY Change	3968.49%	19.28%
Total Long-Term Liabilities	$134.6M	$2.159M
YoY Change	5314.49%	19.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.68M	$36.56M
Total Long-Term Liabilities	$134.6M	$2.159M
Total Liabilities	$174.2M	$159.7M
YoY Change	20.89%	27.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$311.2M	-$298.9M
YoY Change	21.19%	31.16%
Common Stock	$55.00K	$54.00K
YoY Change	34.15%	35.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$118.6M	-$107.8M
YoY Change
Total Liabilities & Shareholders Equity	$55.68M	$51.85M
YoY Change	-10.19%	-20.6%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$12.35M	-$12.54M
YoY Change	-57.33%	-13.87%
Depreciation, Depletion And Amortization	$397.0K	$557.0K
YoY Change	-45.69%	-23.07%
Cash From Operating Activities	$8.446M	$2.809M
YoY Change	-204.78%	-130.99%
INVESTING ACTIVITIES
Capital Expenditures	$26.00K	-$1.717M
YoY Change	-104.88%	1968.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$26.00K	-$1.717M
YoY Change	-95.12%	1968.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	204.0K	-138.0K
YoY Change	-96.26%	-102.27%
NET CHANGE
Cash From Operating Activities	8.446M	2.809M
Cash From Investing Activities	-26.00K	-1.717M
Cash From Financing Activities	204.0K	-138.0K
Net Change In Cash	8.624M	954.0K
YoY Change	-374.65%	-131.07%
FREE CASH FLOW
Cash From Operating Activities	$8.446M	$2.809M
Capital Expenditures	$26.00K	-$1.717M
Free Cash Flow	$8.420M	$4.526M
YoY Change	-211.85%	-150.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Operating Lease Cost OperatingLeaseCost	1267000	usd
	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	usd
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07059
	dei	Entity Central Index Key EntityCentralIndexKey	0001398733
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38599
	dei	Entity Registrant Name EntityRegistrantName	Aquestive Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address Address Line1 EntityAddressAddressLine1	30 Technology Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warren
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3827296
	dei	City Area Code CityAreaCode	908
	dei	Local Phone Number LocalPhoneNumber	941-1900
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	AQST
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54156014	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18649000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28024000	usd
CY2022Q3	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	10737000	usd
CY2021Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	12120000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	6725000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4038000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1976000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3077000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	38087000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	47259000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4284000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5055000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2094000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2725000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1487000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5893000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6903000	usd
CY2022Q3	us-gaap	Assets Assets	51845000	usd
CY2021Q4	us-gaap	Assets Assets	61993000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	11072000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8314000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7733000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8736000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	846000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	899000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	774000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	765000	usd
CY2022Q3	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1910000	usd
CY2021Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1225000	usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	14225000	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	2025000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	36560000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21964000	usd
CY2022Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	38675000	usd
CY2021Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	51551000	usd
CY2022Q3	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	63308000	usd
CY2021Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	59059000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1340000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1946000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	17622000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7122000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2159000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2485000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	159664000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	144127000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53852126	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53852126	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41228736	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41228736	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	54000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	41000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	190982000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	174621000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-298855000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-256796000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-107819000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51845000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61993000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11463000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13287000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36998000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39754000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4625000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4400000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14081000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11623000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3232000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4726000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13203000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12647000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12459000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12129000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41067000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38494000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	20316000	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	21255000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	68351000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	62764000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8853000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7968000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-31353000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23010000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1649000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	2787000	usd
	us-gaap	Interest Expense InterestExpense	4902000	usd
	us-gaap	Interest Expense InterestExpense	8305000	usd
CY2022Q3	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	2039000	usd
CY2021Q3	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	3767000	usd
	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	5837000	usd
	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	10567000	usd
CY2022Q3	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	5000	usd
CY2021Q3	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	-33000	usd
	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	34000	usd
	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	288000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12536000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14555000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42058000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41594000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-12536000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14555000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-42058000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41594000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12536000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14555000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42058000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41594000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53424922	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53424922	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39224863	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39224863	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46828218	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46828218	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37297892	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37297892	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	913000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-93143000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5874000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	15000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2219000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-16302000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-96357000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	642000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-98000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	535000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-3000	usd
CY2022Q3	us-gaap	Stockholders Equity Other StockholdersEquityOther	2000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-12536000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-107819000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-48497000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1507000	usd
CY2021Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	27000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-14672000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-51798000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	76000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1710000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-4000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-53769000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1900000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-9000	usd
CY2021Q3	us-gaap	Stockholders Equity Other StockholdersEquityOther	-1000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14555000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-60345000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-42058000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41594000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1990000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2233000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3667000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5128000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	157000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3604000	usd
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	5683000	usd
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	10457000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-60000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	248000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1257000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	6726000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2687000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	402000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2111000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1793000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2758000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-874000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2357000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2046000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	10509000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3757000	usd
	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	-675000	usd
	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18235000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24918000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	998000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	380000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1500000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2498000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-380000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	3017000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	24592000	usd
	aqst	Proceeds From Issuance Private Offering ProceedsFromIssuancePrivateOffering	3805000	usd
	aqst	Proceeds From Issuance Private Offering ProceedsFromIssuancePrivateOffering	0	usd
	aqst	Proceeds From Issuance And Exercise Of Warrants ProceedsFromIssuanceAndExerciseOfWarrants	5874000	usd
	aqst	Proceeds From Issuance And Exercise Of Warrants ProceedsFromIssuanceAndExerciseOfWarrants	0	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	15000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	76000	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1350000	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11358000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24655000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9375000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-643000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28024000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31807000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18649000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31164000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1609000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	4828000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18649000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-298855000	usd
CY2022Q3	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2150000	usd
CY2021Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3087000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	18396000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7887000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11463000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13287000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36998000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39754000	usd
CY2022Q3	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	731000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	605000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11463000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13287000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36998000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39754000	usd
CY2022Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	9358000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	9678000	usd
CY2022Q3	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2150000	usd
CY2021Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3087000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	1121000	usd
CY2022Q3	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	10737000	usd
CY2021Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	12120000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	605000	usd
	aqst	Accounts Receivable Allowances Credits And Payments AccountsReceivableAllowancesCreditsAndPayments	995000	usd
CY2022Q3	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	731000	usd
	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	1121000	usd
CY2022Q3	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	731000	usd
CY2022Q3	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2229000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	605000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2224000	usd
CY2020Q4	aqst	Days Required Prior To Written Notice DaysRequiredPriorToWrittenNotice	P180D
CY2022Q2	aqst	Pro Rata Portion Of Target Bonus ProRataPortionOfTargetBonus	280000	usd
CY2022Q2	aqst	Cash Payment Representing90 Days Of Base Pay CashPaymentRepresenting90DaysOfBasePay	150000	usd
CY2022Q2	aqst	Days Of Base Pay DaysOfBasePay	90	day
CY2022Q2	us-gaap	Severance Costs1 SeveranceCosts1	263000	usd
CY2022Q2	aqst	Severance Period SeverancePeriod	P18M
CY2022Q2	aqst	Coverage Duration CoverageDuration	P18M
CY2022Q2	aqst	Consulting Fee ConsultingFee	10000	usd
	us-gaap	Depreciation Depreciation	2195000	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1734000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1442000	usd
CY2022Q3	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	2995000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-12536000	usd
CY2021Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	1414000	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1996000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1182000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	6725000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4038000	usd
CY2022Q3	aqst	Number Of Operating Leases NumberOfOperatingLeases	3	lease
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	424000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-42058000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	45913000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44915000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41629000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39860000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4284000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5055000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	557000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	724000	usd
	us-gaap	Depreciation Depreciation	1926000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	110000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	333000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	431000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1294000	usd
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	117000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	352000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	324000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	944000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	565000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	565000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	424000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2822000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	636000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2186000	usd
CY2020Q4	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2867000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2880000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2816000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1487000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	39000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	64000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53424922	shares
CY2022Q3	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	5000000	usd
CY2021Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	6000000	usd
CY2022Q3	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	893000	usd
CY2021Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	903000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5893000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6903000	usd
	aqst	Number Of Guaranteed Royalty Payments NumberOfGuaranteedRoyaltyPayments	8	payment
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53424922	shares
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4939000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5965000	usd
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	351000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	349000	usd
CY2022Q3	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2229000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2224000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	214000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	198000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7733000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8736000	usd
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2019Q3	aqst	Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights	66082000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	18025000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	21888000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	11587000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	51500000	usd
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13822000	usd
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2909000	usd
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39224863	shares
CY2021Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	60284000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	154000	usd
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	5683000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41594000	usd
CY2022Q3	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	1910000	usd
CY2022Q3	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	65218000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-12536000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14555000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-42058000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41594000	usd
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39224863	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46828218	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46828218	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37297892	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37297892	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14555000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	535000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1900000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3669000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5128000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	535000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1900000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3669000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5128000	usd
CY2022Q3	aqst	Inducement Equity Common Stock Options Award Shares InducementEquityCommonStockOptionsAwardShares	100000	shares
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd

Files In Submission

Name	View Source	Status
0001628280-22-027580-index-headers.html	Edgar Link	pending
0001628280-22-027580-index.html	Edgar Link	pending
0001628280-22-027580.txt	Edgar Link	pending
0001628280-22-027580-xbrl.zip	Edgar Link	pending
aqst-09302022ex311.htm	Edgar Link	pending
aqst-09302022ex312.htm	Edgar Link	pending
aqst-09302022ex321.htm	Edgar Link	pending
aqst-09302022ex322.htm	Edgar Link	pending
aqst-20220930.htm	Edgar Link	pending
aqst-20220930.xsd	Edgar Link	pending
atnahspharmauklimitedlic.htm	Edgar Link	pending
atnahspharmauklimitedlic001.jpg	Edgar Link	pending
atnahspharmauklimitedlic002.jpg	Edgar Link	pending
atnahspharmauklimitedlic003.jpg	Edgar Link	pending
atnahspharmauklimitedlic004.jpg	Edgar Link	pending
atnahspharmauklimitedlic005.jpg	Edgar Link	pending
atnahspharmauklimitedlic006.jpg	Edgar Link	pending
atnahspharmauklimitedlic007.jpg	Edgar Link	pending
atnahspharmauklimitedlic008.jpg	Edgar Link	pending
atnahspharmauklimitedlic009.jpg	Edgar Link	pending
atnahspharmauklimitedlic010.jpg	Edgar Link	pending
atnahspharmauklimitedlic011.jpg	Edgar Link	pending
atnahspharmauklimitedlic012.jpg	Edgar Link	pending
atnahspharmauklimitedlic013.jpg	Edgar Link	pending
atnahspharmauklimitedlic014.jpg	Edgar Link	pending
atnahspharmauklimitedlic015.jpg	Edgar Link	pending
atnahspharmauklimitedlic016.jpg	Edgar Link	pending
atnahspharmauklimitedlic017.jpg	Edgar Link	pending
aqst-20220930_cal.xml	Edgar Link	unprocessable
aqst-20220930_pre.xml	Edgar Link	unprocessable
aqst-20220930_lab.xml	Edgar Link	unprocessable
aqst-20220930_def.xml	Edgar Link	unprocessable
aqst-20220930_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
atnahspharmauklimitedlic018.jpg	Edgar Link	pending
atnahspharmauklimitedlic019.jpg	Edgar Link	pending
atnahspharmauklimitedlic020.jpg	Edgar Link	pending
atnahspharmauklimitedlic021.jpg	Edgar Link	pending
atnahspharmauklimitedlic022.jpg	Edgar Link	pending
atnahspharmauklimitedlic023.jpg	Edgar Link	pending
atnahspharmauklimitedlic024.jpg	Edgar Link	pending
atnahspharmauklimitedlic025.jpg	Edgar Link	pending
atnahspharmauklimitedlic026.jpg	Edgar Link	pending
atnahspharmauklimitedlic027.jpg	Edgar Link	pending
atnahspharmauklimitedlic028.jpg	Edgar Link	pending
atnahspharmauklimitedlic029.jpg	Edgar Link	pending
atnahspharmauklimitedlic030.jpg	Edgar Link	pending
atnahspharmauklimitedlic031.jpg	Edgar Link	pending
atnahspharmauklimitedlic032.jpg	Edgar Link	pending
atnahspharmauklimitedlic033.jpg	Edgar Link	pending
atnahspharmauklimitedlic034.jpg	Edgar Link	pending
atnahspharmauklimitedlic035.jpg	Edgar Link	pending
atnahspharmauklimitedlic036.jpg	Edgar Link	pending
atnahspharmauklimitedlic037.jpg	Edgar Link	pending
atnahspharmauklimitedlic038.jpg	Edgar Link	pending
atnahspharmauklimitedlic039.jpg	Edgar Link	pending
atnahspharmauklimitedlic040.jpg	Edgar Link	pending
atnahspharmauklimitedlic041.jpg	Edgar Link	pending
atnahspharmauklimitedlic042.jpg	Edgar Link	pending
atnahspharmauklimitedlic043.jpg	Edgar Link	pending
atnahspharmauklimitedlic044.jpg	Edgar Link	pending
atnahspharmauklimitedlic045.jpg	Edgar Link	pending
atnahspharmauklimitedlic046.jpg	Edgar Link	pending
atnahspharmauklimitedlic047.jpg	Edgar Link	pending
atnahspharmauklimitedlic048.jpg	Edgar Link	pending
atnahspharmauklimitedlic049.jpg	Edgar Link	pending
atnahspharmauklimitedlic050.jpg	Edgar Link	pending
atnahspharmauklimitedlic051.jpg	Edgar Link	pending
atnahspharmauklimitedlic052.jpg	Edgar Link	pending
atnahspharmauklimitedlic053.jpg	Edgar Link	pending
atnahspharmauklimitedlic054.jpg	Edgar Link	pending
atnahspharmauklimitedlic055.jpg	Edgar Link	pending
atnahspharmauklimitedlic056.jpg	Edgar Link	pending
atnahspharmauklimitedlic057.jpg	Edgar Link	pending
atnahspharmauklimitedlic058.jpg	Edgar Link	pending
atnahspharmauklimitedlic059.jpg	Edgar Link	pending
atnahspharmauklimitedlic060.jpg	Edgar Link	pending
atnahspharmauklimitedlic061.jpg	Edgar Link	pending
atnahspharmauklimitedlic062.jpg	Edgar Link	pending
atnahspharmauklimitedlic063.jpg	Edgar Link	pending
atnahspharmauklimitedlic064.jpg	Edgar Link	pending
atnahspharmauklimitedlic065.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQST
Aquestive Therapeutics, Inc. Stock $aqst

2022 Q4 Form 10-Q Financial Statement

#000162828022027580 Filed on November 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST Aquestive Therapeutics, Inc. Stock $aqst

2022 Q4 Form 10-Q Financial Statement

#000162828022027580 Filed on November 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST
Aquestive Therapeutics, Inc. Stock $aqst